A Phase 4 interventional study of Apixaban and vitamin K antagonist in Acute Coronary Syndromes, sponsored by Bristol-Myers Squibb. Completed at 626 sites in 37 countries. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2020-06-11.
Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 265 studies in Acute Coronary Syndrome with a site in United States — 14 open to participants now, 21 under way, 2 of them phase 3. Acute Coronary Syndrome · United States.
Among the 265 studies in Acute Coronary Syndrome with a site in United States, this one is the 28th largest by enrollment of the 186 interventional ones that give a count, is one of 9 that started in 2015, is one of 27 in phase 4, and was the 161st registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →14 of the 265 studies in Acute Coronary Syndrome with a site in United States are open now. Recruiting first, the newest first:
Teleflex · Sites in United States, France, Latvia and 1 more country
Ages 18–80
Shanghai CureGene Pharmaceutical Co., Ltd. · Sites in United States
Ages 18–55 · Healthy volunteers
Columbia University · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of South Florida · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
265 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 36 · Phase 3 41 · Phase 4 27
First in 2001; this study’s year is marked. 9 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,614 is above the median of 200 across 867 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 150 across the 186 interventional studies, 500 across the 79 observational. Of the 214 that completed or were terminated, 97 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
91 of 265 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 4 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Acute Coronary Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05918861Phase 3DalCor PharmaceuticalsEffect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | 2027-08 |
| NCT06481943SB Technology, Inc.A Prospective Research Investigation of Ischemia Using MCG | 2026-12 |
| NCT05412927Angel Medical SystemsAngelMed Guardian® System PMA Post Approval Study | 2026-12 |
| NCT04496687SCAD AllianceInternational Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry | 2026-12-31 |
| NCT06927739AbcentraFocused Orticumab Research for Treating Inflammation in Coronary Arteries | 2027-02-08 |
Add all 7 to your calendar (.ics) → With an account.
Among the 265 studies in Acute Coronary Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if Apixaban is safer than a Vitamin K Antagonist given for 6 months in terms of bleeding in patients with an irregular heart beat (atrial fibrillation) and a recent heart attack or a recent procedure to open up a blood vessel in the heart. All patients would also be taking a class of medicines called P2Y12 inhibitors (such as clopidogrel/Plavix) and be treated for up to 6 months. The primary focus will be a comparison of the bleeding risk of Apixaban, with or without aspirin, versus a Vitamin K antagonist, such as warfarin, with or without aspirin.
Patients will be recruited from either inpatient coronary care or general medical units, or recruited from outpatient cardiology offices.
Masking:
Apixaban: Open label.
VKA: Open label.
Acetylsalicylic acid film coated tablet: Double Blinded.
Placebo matching Acetylsalicylic acid film coated tablet: Double Blinded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 mg or 2.5 mg Apixaban tablets orally twice per day
Drug: Apixaban
VKA tablets orally once daily
Drug: vitamin K antagonist
81 mg Acetylsalicylic acid film coated tablet orally once daily
Drug: Acetylsalicylic acid
Placebo matching Acetylsalicylic acid film coated tablet once daily
Other: Acetylsalicylic acid placebo
Also known as: BMS-562247
Also known as: Aspirin 81 mg
Also known as: aspirin placebo
The Rate of International Society on Thrombosis and Haemostasis (ISTH) Major or Clinically Relevant Non-Major (CRNM) Bleeding With Apixaban Versus Vitamin K Antagonist (VKA) During the Treatment Period
Time to first ISTH major or CRNM bleeding during the 6-month period of treatment with Apixaban or VKA. N is the number of participants treated with Apixaban or VKA. n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with major or CRNM bleeding divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.
Time frame: Approximately 6 months
The Rate of ISTH Major or CRNM Bleeding With Aspirin Versus no Aspirin During the Treatment Period
Time to first ISTH major or CRNM bleeding during the treatment period of 6 months with aspirin or placebo. N is the number of participants with aspirin or placebo. n is the number of participants treated with aspirin or placebo with major or CRNM bleeding in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.
Time frame: Approximately 6 months
Superiority on ISTH Major or CRNM Bleeding for Apixaban Versus VKA
Time to first occurrence during the time the participants were treated with Apixaban or VKA. N is the number of participants treated with Apixaban or VKA. n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.
Time frame: Approximately 6 months
The Rate of All-cause Death or All-cause Rehospitalization With Apixaban Versus VKA
Time to first all-cause death or all-cause hospitalization during the during the 6-month treatment period with Apixaban or VKA. N is the number of participants treated with Apixaban or VKA. n is the number of participants treated with Apixaban or VKA with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.
Time frame: Approximately 6 months
The Rate of All-cause Death or All-cause Rehospitalization With Aspirn Versus no Aspirin
Time to first all-cause death or all-cause hospitalization during the 6-month period of treatment with aspirin or placebo. N is the number of participants treated with aspirin or placebo. n is the number of participants treated with aspirin or placebo with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.
Time frame: Approximately 6 months
The Rate of the Composite Endpoint of Death or Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Apixaban Versus VKA
Time to first occurrence during the 6-month treatment period with Apixaban or VKA. N is the number of participants treated with Apixaban or VKA. n is the number of participants treated with Apixaban or VKA with death or ischemic events in each treatment group during the during the 6-month period of treatment. Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.
Time frame: Approximately 6 months
The Composite Endpoints of Death and Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Aspirin Versus no Aspirin
Time to first death or ischenic event during the 6-month treatment period with aspirin or placebo. N is the number of participants treated with aspirin or placebo. n is the number of participants treated with aspirin or placebo with death or ischemic events in each treatment group during the 6-month treatment period. Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.
Time frame: Approximately 6 months
| Milestone | Apixaban With Acetylsalicylic Acid Film Coated Tablet | Apixaban With Placebo Matching Acetylsalicylic Acid | Vitamin K Antagonist (VKA) With Acetylsalicylic Acid | VKA With Placebo Matching Acetylsalicylic Acid |
|---|---|---|---|---|
| Started | 1153 | 1153 | 1154 | 1154 |
| Completed | 1087 | 1091 | 1069 | 1071 |
| Not completed | 66 | 62 | 85 | 83 |
| Withdrew: Adverse event | 0 | 1 | 1 | 2 |
| Withdrew: Participant request to stop therapy | 4 | 3 | 8 | 6 |
| Withdrew: Participant withdrew consent | 14 | 12 | 30 | 21 |
| Withdrew: Death | 39 | 41 | 35 | 42 |
| Withdrew: Lost to follow-up | 3 | 3 | 2 | 5 |
| Withdrew: Poor/non-compliance | 0 | 1 | 3 | 4 |
| Withdrew: Participant no longer meets criteria | 2 | 0 | 0 | 1 |
| Withdrew: Participant doesn't answer phone | 1 | 0 | 0 | 0 |
| Withdrew: Participant wanted home visits | 1 | 0 | 0 | 0 |
| Withdrew: Randomized in error | 2 | 0 | 0 | 0 |
| Withdrew: No study drug on site | 0 | 1 | 0 | 0 |
| Withdrew: Stroke and stroke rehabilitation | 0 | 0 | 1 | 0 |
| Withdrew: Coagulation values cannot be set | 0 | 0 | 1 | 0 |
| Withdrew: State regulations prevent participation | 0 | 0 | 1 | 0 |
| Withdrew: Poor treatment monitoring | 0 | 0 | 1 | 0 |
| Withdrew: Participant in jail | 0 | 0 | 1 | 0 |
| Withdrew: Investigator decision | 0 | 0 | 1 | 1 |
| Withdrew: Site closure; participant won't transfer | 0 | 0 | 0 | 1 |
Time to first ISTH major or CRNM bleeding during the 6-month period of treatment with Apixaban or VKA. N is the number of participants treated with Apixaban or VKA. n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with major or CRNM bleeding divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.
| Percentage per year | Apixaban | Vitamin K Antagonist |
|---|---|---|
| The Rate of International Society on Thrombosis and Haemostasis (ISTH) Major or Clinically Relevant Non-Major (CRNM) Bleeding With Apixaban Versus Vitamin K Antagonist (VKA) During the Treatment Period | 24.66 | 35.79 |
Time to first ISTH major or CRNM bleeding during the treatment period of 6 months with aspirin or placebo. N is the number of participants with aspirin or placebo. n is the number of participants treated with aspirin or placebo with major or CRNM bleeding in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.
| Percentage per year | Acetylsalicylic Acid Film Coated Tablet | Placebo Matching Acetylsalicylic Acid Film Coated Tablet |
|---|---|---|
| The Rate of ISTH Major or CRNM Bleeding With Aspirin Versus no Aspirin During the Treatment Period | 40.51 | 21.03 |
Time to first occurrence during the time the participants were treated with Apixaban or VKA. N is the number of participants treated with Apixaban or VKA. n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.
| Percentage per year | Apixaban | Vitamin K Antagonist |
|---|---|---|
| Superiority on ISTH Major or CRNM Bleeding for Apixaban Versus VKA | 24.66 | 35.79 |
Time to first all-cause death or all-cause hospitalization during the during the 6-month treatment period with Apixaban or VKA. N is the number of participants treated with Apixaban or VKA. n is the number of participants treated with Apixaban or VKA with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.
| Percentage per year | Apixaban | Vitamin K Antagonist |
|---|---|---|
| The Rate of All-cause Death or All-cause Rehospitalization With Apixaban Versus VKA | 57.24 | 69.19 |
Time to first all-cause death or all-cause hospitalization during the 6-month period of treatment with aspirin or placebo. N is the number of participants treated with aspirin or placebo. n is the number of participants treated with aspirin or placebo with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment. Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.
| Percentage per year | Acetylsalicylic Acid Film Coated Tablet | Placebo Matching Acetylsalicylic Acid Film Coated Tablet |
|---|---|---|
| The Rate of All-cause Death or All-cause Rehospitalization With Aspirn Versus no Aspirin | 65.72 | 60.56 |
Time to first occurrence during the 6-month treatment period with Apixaban or VKA. N is the number of participants treated with Apixaban or VKA. n is the number of participants treated with Apixaban or VKA with death or ischemic events in each treatment group during the during the 6-month period of treatment. Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.
| Percentage per year | Apixaban | Vitamin K Antagonist |
|---|---|---|
| The Rate of the Composite Endpoint of Death or Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Apixaban Versus VKA | 15.85 | 17.17 |
Time to first death or ischenic event during the 6-month treatment period with aspirin or placebo. N is the number of participants treated with aspirin or placebo. n is the number of participants treated with aspirin or placebo with death or ischemic events in each treatment group during the 6-month treatment period. Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year.
| Percentage per year | Acetylsalicylic Acid Film Coated Tablet | Placebo Matching Acetylsalicylic Acid Film Coated Tablet |
|---|---|---|
| The Composite Endpoints of Death and Ischemic Events (Stroke, Myocardial Infarction, Stent Thrombosis, Urgent Revascularization) With Aspirin Versus no Aspirin | 15.28 | 17.73 |
Collected over Includes adverse events (AEs) with onset on or after the first dose of study medication through 2 days (for non-serious AE) or 30 days (for serious AE) after the last dose of study medication (approximately 7 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apixaban With Acetylsalicylic Acid Film Coated Tablet | 42/1,145 (3.7%) | 53/1,145 (4.6%) | 35/1,145 (3.1%) |
| Apixaban With Placebo Matching Acetylsalicylic Acid | 46/1,143 (4%) | 50/1,143 (4.4%) | 21/1,143 (1.8%) |
| Vitamin K Antagonist (VKA) With Acetylsalicylic Acid | 38/1,123 (3.4%) | 52/1,123 (4.6%) | 33/1,123 (2.9%) |
| VKA With Placebo Matching Acetylsalicylic Acid | 42/1,127 (3.7%) | 55/1,126 (4.9%) | 18/1,126 (1.6%) |
| APIXABAN ONLY | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| VKA ONLY | 3/10 (30%) | 3/10 (30%) | 1/10 (10%) |
| ACETYLSALICLIC ACID ONLY | 0/9 (0%) | 0/9 (0%) | 3/9 (33.3%) |
| PLACEBO MATCHING ACETYLSALICLIC ACID ONLY | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Event | Apixaban With Acetylsalicylic Acid Film Coated Tablet | Apixaban With Placebo Matching Acetylsalicylic Acid | Vitamin K Antagonist (VKA) With Acetylsalicylic Acid | VKA With Placebo Matching Acetylsalicylic Acid | APIXABAN ONLY | VKA ONLY | ACETYLSALICLIC ACID ONLY | PLACEBO MATCHING ACETYLSALICLIC ACID ONLY |
|---|---|---|---|---|---|---|---|---|
| Cardiac failureCardiac disorders | 1/1145 | 9/1143 | 5/1123 | 3/1126 | 0/2 | 1/10 | 0/9 | 0/10 |
| Cerebral haemorrhageNervous system disorders | 0/1145 | 0/1143 | 0/1123 | 2/1126 | 0/2 | 1/10 | 0/9 | 0/10 |
| Peripheral ischaemiaVascular disorders | 1/1145 | 0/1143 | 0/1123 | 0/1126 | 0/2 | 1/10 | 0/9 | 0/10 |
| Acute myocardial infarctionCardiac disorders | 3/1145 | 1/1143 | 6/1123 | 3/1126 | 0/2 | 0/10 | 0/9 | 0/10 |
| Myocardial infarctionCardiac disorders | 4/1145 | 5/1143 | 5/1123 | 2/1126 | 0/2 | 0/10 | 0/9 | 0/10 |
| OverdoseInjury, poisoning and procedural complications | 2/1145 | 0/1143 | 5/1123 | 1/1126 | 0/2 | 0/10 | 0/9 | 0/10 |
| Sudden deathGeneral disorders | 5/1145 | 3/1143 | 2/1123 | 1/1126 | 0/2 | 0/10 | 0/9 | 0/10 |
| Accidental overdoseInjury, poisoning and procedural complications | 1/1145 | 1/1143 | 1/1123 | 4/1126 | 0/2 | 0/10 | 0/9 | 0/10 |
| Cardiac arrestCardiac disorders | 2/1145 | 3/1143 | 3/1123 | 3/1126 | 0/2 | 0/10 | 0/9 | 0/10 |
| Ischaemic strokeNervous system disorders | 0/1145 | 0/1143 | 3/1123 | 0/1126 | 0/2 | 0/10 | 0/9 | 0/10 |
| Event | Apixaban With Acetylsalicylic Acid Film Coated Tablet | Apixaban With Placebo Matching Acetylsalicylic Acid | Vitamin K Antagonist (VKA) With Acetylsalicylic Acid | VKA With Placebo Matching Acetylsalicylic Acid | APIXABAN ONLY | VKA ONLY | ACETYLSALICLIC ACID ONLY | PLACEBO MATCHING ACETYLSALICLIC ACID ONLY |
|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 16/1145 | 3/1143 | 10/1123 | 6/1126 | 0/2 | 0/10 | 1/9 | 0/10 |
| Cardiac failureCardiac disorders | 8/1145 | 8/1143 | 9/1123 | 5/1126 | 0/2 | 0/10 | 1/9 | 0/10 |
| Puncture site reactionGeneral disorders | 0/1145 | 0/1143 | 0/1123 | 0/1126 | 0/2 | 0/10 | 1/9 | 0/10 |
| PneumoniaInfections and infestations | 5/1145 | 1/1143 | 2/1123 | 2/1126 | 0/2 | 0/10 | 1/9 | 0/10 |
| Vascular pseudoaneurysmInjury, poisoning and procedural complications | 0/1145 | 0/1143 | 1/1123 | 0/1126 | 0/2 | 0/10 | 1/9 | 0/10 |
| Acute kidney injuryRenal and urinary disorders | 9/1145 | 3/1143 | 5/1123 | 2/1126 | 0/2 | 0/10 | 1/9 | 0/10 |
| HaematomaVascular disorders | 4/1145 | 3/1143 | 6/1123 | 1/1126 | 0/2 | 0/10 | 1/9 | 0/10 |
| HaematuriaRenal and urinary disorders | 2/1145 | 3/1143 | 5/1123 | 3/1126 | 0/2 | 1/10 | 0/9 | 0/10 |
| Age, Continuous(Years) | Apixaban With Acetylsalicylic Acid Film Coated Tablet | Apixaban With Placebo Matching Acetylsalicylic Acid | Vitamin K Antagonist (VKA) With Acetylsalicylic | VKA With Placebo Matching Acetylsalicylic Acid | Total |
|---|---|---|---|---|---|
| Mean | 70.2 ± 9.12 | 69.3 ± 9.32 | 70.0 ± 9.09 | 70.0 ± 9.13 | 69.9 ± 9.17 |
| Age, Customized(Participants) | Apixaban With Acetylsalicylic Acid Film Coated Tablet | Apixaban With Placebo Matching Acetylsalicylic Acid | Vitamin K Antagonist (VKA) With Acetylsalicylic | VKA With Placebo Matching Acetylsalicylic Acid | Total |
|---|---|---|---|---|---|
| < 65 years old | 308 | 333 | 311 | 315 | 1267 |
| 65-80 years old | 664 | 660 | 662 | 657 | 2643 |
| >=80 | 181 | 160 | 181 | 182 | 704 |
| Sex: Female, Male(Participants) | Apixaban With Acetylsalicylic Acid Film Coated Tablet | Apixaban With Placebo Matching Acetylsalicylic Acid | Vitamin K Antagonist (VKA) With Acetylsalicylic | VKA With Placebo Matching Acetylsalicylic Acid | Total |
|---|---|---|---|---|---|
| Female | 357 | 313 | 339 | 328 | 1337 |
| Male | 796 | 840 | 815 | 826 | 3277 |
| Ethnicity (NIH/OMB)(Participants) | Apixaban With Acetylsalicylic Acid Film Coated Tablet | Apixaban With Placebo Matching Acetylsalicylic Acid | Vitamin K Antagonist (VKA) With Acetylsalicylic | VKA With Placebo Matching Acetylsalicylic Acid | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 10 | 7 | 5 | 24 |
| Not Hispanic or Latino | 114 | 123 | 120 | 126 | 483 |
| Unknown or Not Reported | 1037 | 1020 | 1027 | 1023 | 4107 |
| Race/Ethnicity, Customized(Participants) | Apixaban With Acetylsalicylic Acid Film Coated Tablet | Apixaban With Placebo Matching Acetylsalicylic Acid | Vitamin K Antagonist (VKA) With Acetylsalicylic | VKA With Placebo Matching Acetylsalicylic Acid | Total |
|---|---|---|---|---|---|
| White | 1039 | 1058 | 1043 | 1044 | 4184 |
| Black/African American | 17 | 12 | 12 | 18 | 59 |
| Asian | 35 | 35 | 39 | 31 | 140 |
| American Indian/Alaska Native | 4 | 6 | 2 | 4 | 16 |
| Native Hawaiian/Other Pacific Islander | 0 | 0 | 0 | 1 | 1 |
| Other | 47 | 29 | 38 | 43 | 157 |
| Not Reported | 11 | 13 | 20 | 13 | 57 |
Showing the first 100 of 626 sites across 37 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2015 to primary completion in Nov 2018, 41 months.
Results were first posted in Feb 2020, 1 year 2 months after primary completion.
Of 92 phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 41 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Apixaban · Vitamin K Antagonist